Doxefazepam

Doxefazepam
	File:Doxefazepam.svg
Clinical data
Pregnancy; category	?;
Routes of; administration	Oral
ATC code	N05CD12 (WHO) ;
Legal status
Legal status	Schedule IV(US);
Pharmacokinetic data
Bioavailability	?
Metabolism	Hepatic
Elimination half-life	3-4 hours
Excretion	Renal
Identifiers
	IUPAC name 9-chloro-6-(2-fluorophenyl)-4-hydroxy; -2-(2-hydroxyethyl)-2,5-diazabicyclo; [5.4.0]undeca-5,8,10,12-tetraen-3-one;
CAS Number	40762-15-0 ;
PubChem CID	38668;
DrugBank	? ;
ChemSpider	35431 ;
UNII	verifiedrevid = 457288969 231RV72C8L verifiedrevid = 457288969;
KEGG	D07327 ;
ChEMBL	ChEMBL64677 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C17H14ClFN2O3
Molar mass	348.8
3D model (JSmol)	Interactive image;
	SMILES FC1=CC=CC=C1C2=NC(C(N(CCO)C3=C2C=C(C=C3)Cl)=O)O;
	InChI InChI=1S/C17H14ClFN2O3/c18-10-5-6-14-12(9-10)15(11-3-1-2-4-13(11)19)20-16(23)17(24)21(14)7-8-22/h1-6,9,16,22-23H,7-8H2 ; Key:VOJLELRQLPENHL-UHFFFAOYSA-N ;
(what is this?)

Doxefazepam (marketed under brand name Doxans) is a benzodiazepine derivative drug developed by Schiapparelli in the 1970s.^[2] It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. It is used therapeutically as a hypnotic.^[3] According to Babbini and colleagues in 1975, this derivative of flurazepam was between 2 and 4 times more potent than the latter while at the same time being half as toxic in laboratory animals.^[4] Section 5.5 of the article Doxefazepam in volume 66 of the World Health Organization's (WHO) and International Agency for Research on Cancer's (IARC) IARC Monographs On The Evaluation Of Carcinogenic Risks To Humans, an article describing the carcinogenic/toxic effects of doxefazepam on humans and experimental animals, states that there is "inadequate evidence in humans for the carcinogenicity of doxefazepam" and limited evidence in experimental for the carcinogenicity of doxefazepam," and concluded that the overall evaluation of the substance's carcinogenicity to humans is "not classifiable."^[5]

References

↑ http://www.intox.org/databank/documents/pharm/doxefzpm/iarc796.htm
↑ DE Patent 2338058 - BENZODIAZEPINVERBINDUNGEN FUER DIE THERAPIE
↑ Rodriguez, G; Rosadini, G; Sannita, WG; Strumia, E (1984). "Effects of doxefazepam on normal sleep. An EEG and neuropsychological study". Neuropsychobiology. 11 (2): 133–9. doi:10.1159/000118066. PMID 6483162.
↑ Babbini, M. (August 1975). "Sedative-hypnotic properties of a new benzodiazepine in comparison with flurazepam. Pharmacological and clinical findings". Arzneimittel-Forschung. 25 (8): 1294–1300. PMID 241364. Unknown parameter |coauthors= ignored (help)
↑ "Doxefazepam" (PDF). IARC Monographs On The Evaluation Of Carcinogenic Risks To Humans. International Agency For Research On Cancer (IARC). 66: 97–104. 13–20 Feb 1996. Retrieved 10 July 2014.

External links

Template:Benzodiazepines

Template:GABAAR PAMs

Template:Sedative-stub

[1] ttp://www.intox.org/databank/documents/pharm/doxefzpm/iarc796.htm

[2] DE Patent 2338058 - BENZODIAZEPINVERBINDUNGEN FUER DIE THERAPIE

[3] Rodriguez, G; Rosadini, G; Sannita, WG; Strumia, E (1984). "Effects of doxefazepam on normal sleep. An EEG and neuropsychological study". Neuropsychobiology. 11 (2): 133–9. doi:10.1159/000118066. PMID 6483162.

[SAS_643_1975-4] Babbini, M. (August 1975). "Sedative-hypnotic properties of a new benzodiazepine in comparison with flurazepam. Pharmacological and clinical findings". Arzneimittel-Forschung. 25 (8): 1294–1300. PMID 241364. Unknown parameter |coauthors= ignored (help)

[5] "Doxefazepam" (PDF). IARC Monographs On The Evaluation Of Carcinogenic Risks To Humans. International Agency For Research On Cancer (IARC). 66: 97–104. 13–20 Feb 1996. Retrieved 10 July 2014.

[1]

[2]

[3]

[4]

[5]

Doxefazepam

See also

References

External links

Navigation menu

Clinical data
File:Doxefazepam.svg

Pregnancy category	?
Routes of administration	Oral
ATC code	N05CD12 (WHO)
Legal status
Legal status	Schedule IV(US)
Pharmacokinetic data
Bioavailability	?
Metabolism	Hepatic
Elimination half-life	3-4 hours^[1]
Excretion	Renal
Identifiers
IUPAC name 9-chloro-6-(2-fluorophenyl)-4-hydroxy -2-(2-hydroxyethyl)-2,5-diazabicyclo [5.4.0]undeca-5,8,10,12-tetraen-3-one
CAS Number	40762-15-0^N
PubChem CID	38668
DrugBank	?^N
ChemSpider	35431^Y
UNII	verifiedrevid = 457288969 231RV72C8L verifiedrevid = 457288969
KEGG	D07327^Y
ChEMBL	ChEMBL64677^Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₁₇H₁₄ClFN₂O₃
Molar mass	348.8
3D model (JSmol)	Interactive image
SMILES FC1=CC=CC=C1C2=NC(C(N(CCO)C3=C2C=C(C=C3)Cl)=O)O
InChI InChI=1S/C17H14ClFN2O3/c18-10-5-6-14-12(9-10)15(11-3-1-2-4-13(11)19)20-16(23)17(24)21(14)7-8-22/h1-6,9,16,22-23H,7-8H2^Y Key:VOJLELRQLPENHL-UHFFFAOYSA-N^Y
^NY (what is this?)